期刊文献+

健择联合腹腔灌注顺铂治疗胆系恶性肿瘤的临床研究

Combination of gemcitabine intravenous injection and cisplatin peritoneal perfusion for biliary malignancies
暂未订购
导出
摘要 目的研究健择联合顺铂进行腹腔区域性热化疗治疗恶性胆系肿瘤的疗效,寻找合适的恶性胆系肿瘤内科治疗方案。方法分别选择全身静脉应用健择联合腹腔灌注顺铂结合体外射频热疗(试验组,n=24)、全身静脉应用吡柔比星联合腹腔灌注顺铂(对照组,n=25)对胆系恶性肿瘤进行治疗,比较治疗效果。结果全身静脉应用健择联合腹腔灌注顺铂结合体外射频热疗实验组的有效率和临床获益率均明显高于全身静脉应用吡柔比星联合腹腔灌注顺铂对照组(P<0.05,P<0.01);试验组的生活质量评分明显优于对照组(P<0.01)。结论全身静脉应用健择联合腹腔灌注顺铂结合体外射频热疗对恶性胆系肿瘤有明显的治疗效果,毒副作用小,患者可耐受。 Objective To study the effects of gemcitabine and cisplatin combination in the treatment of malignancies of biliary tree and investigate proper chemotherapeutic regimens. Methods Twenty-four patients with malignancies of biliary tree were treated with gemcitabine intravenous injection and cisplatin intraperitoneal perfusion, followed by RF thermotherapy at the hepatic region ( experiment group), 25 patients applied to pirarubicin intravenous injection and cisplatin intraperitoneal perfusion (control group). The curative effects were analyzed. Results Forty-nine patients all completed the treatment. The overall response rate and clinical profit rate were higher in experiment group than control group (P 〈0.05 and P 〈0.01 ). The quality of life score was higher in experiment group than control group (P 〈0.01 ). Conclusion The combination of gemcitabine intravenous injection and cisplatin intraperitoneal perfusion has significant curative effect on malignancies of biliary tree, with fewer side effects and more tolerance to patients.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2006年第11期1243-1245,共3页 Journal of Third Military Medical University
关键词 胆系肿瘤 射频热疗 疗效 腹腔灌注 malignancy of biliary tree radiofrequency hyperthermia curative effect peritoneal perfusion
  • 相关文献

参考文献12

  • 1Van-DER-ZEE J,GONZALEZ-GONZALEZ D,Van-RHOON G C,et al.Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours:a prospective,randomised,multicentre trial.Dutch Deep Hyperthermia Group[J].Lancet,2000,355(9210):1119-1125.
  • 2WESSALOWSKI R,Van-HEEK-ROMANOWSKI R,ISSELS R D,et al.Estimated number of children with cancer eligible for hyperthermia based on population-and treatment-related criteria[J].Int J Hyperthermia,1999,15 (6):455-466.
  • 3FALK M H,ISSELS R D.Hyperthermia in oncology[J].Int J Hyperthermia,2001,17(1):1-18.
  • 4CASTRO M P.Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma:a case report[J].Cancer,1998,82(4):639-641.
  • 5闫敏,宋三泰,江泽飞,张少华,刘晓晴,徐建明,王涛,罗卫东.乳腺癌骨转移内分泌治疗与化疗的对比研究[J].中华肿瘤杂志,2004,26(3):177-180. 被引量:25
  • 6郝春芳,江泽飞,宋三泰,刘晓晴,王涛,申戈,张志强,秦燕.来曲唑治疗晚期乳腺癌的临床观察[J].肿瘤研究与临床,2004,16(2):100-102. 被引量:12
  • 7ROSSI C R,DERACO M,DE-SIMONE M,et al.Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis:clinical outcome and prognostic factors in 60 consecutive patients[J].Cancer,2004,100(9):1943-1950.
  • 8ROSSI C R,FOLETTO M,MOCELLIN S,et al.Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis:phase I study[J].Cancer,2002,94(2):492-499.
  • 9PITT H A,NAKEEB A,ABRAMS R A,et al.Perihilar cholangiocarcinoma.Postoperative radiotherapy does not improve survival[J].Ann Surg,1995,221(6):788-798.
  • 10KHAN S A,THOMAS H C,DAVIDSON B R,et al.Cholangiocarcinoma[J].Lancet,2005,366(9493):1303-1314.

二级参考文献15

  • 1宋三泰.乳癌内分泌治疗应该注意的几个问题[J].中国实用外科杂志,1997,17(2):70-72. 被引量:6
  • 2Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer, 2000,7: 271-284.
  • 3Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981,47 : 207-214.
  • 4Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol, 2002, 29:134-144.
  • 5Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase Ⅲ study of the International Letrozole Breast Cancer Group. J Clin Oncol, 2001,19:2596-2606.
  • 6Robertson J, Howell A, Buzdar A, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat, 1999,58: 157-162.
  • 7Mouridsen H, C, ershanovich M, Sun Y, et al. Superior eefficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:, results of a phase Ⅲ study of the international letrozole breast cancer group [J].
  • 8Robertson J, Buzdar A, Howell A, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer[J]. Breast Cancer Res Treat, 1999,58 (2):157-162.
  • 9Dombemowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J]. J Clin Oncol, 19
  • 10Gershanovich M, Chaudri H, Campos D, et al. Letrozole, a new oral aromatase inhibitor:, randomized trial comparing 2.5mg daily, 0.5ug daily and aminoglutethimide in postmenopausal women with advanced breast cancer[J]. Ann Oncol, 1998,9(6): 639-645.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部